Adverse Events Related to Tirzepatide.
Rahul MishraRishi RajGhada ElshimyIsain ZapataLakshmi KannanPriyanka MajetyDinesh EdemRiccardo CorreaPublished in: Journal of the Endocrine Society (2023)
Tirzepatide is associated with a dose-dependent increase in incidence of GI AEs and AEs leading to drug discontinuation. Severe hypoglycemia, fatal AEs, acute pancreatitis, cholelithiasis, and cholecystitis are rare with this medication.